Hebang Biotech's stock price has increased by over 20% in the past three trading days, with an expected net loss of more than 470 million yuan in 2025.

NightAirdropper · 2026-02-28T08:31:45+00:00

Sichuan Hebang Biotechnology Co., Ltd. issued an announcement due to its stock price rising more than 20% for three consecutive days, confirming normal operations with no significant impact factors. Meanwhile, it is expected that the net profit will decline by 470 million to 570 million yuan in 2025, and the company plans to reduce holdings by no more than 177 million shares. The company's business includes chemicals, pesticides, and other areas, facing a high risk warning.

NightAirdropper

2026-02-28 08:31:45

Abstract generation in progress

Radar Finance | Written by Feng Xiuyu | Edited by Li Yihui

On February 26, Sichuan Hebang Biotechnology Co., Ltd. (Stock abbreviation: Hebang Biotech, Stock code: 603077) issued an announcement regarding abnormal stock trading fluctuations. The company’s stock closing prices on February 24, 25, and 26, 2026, deviated by more than 20% cumulatively over three consecutive trading days, indicating abnormal trading activity. After self-examination, the company’s production and operations are normal, there have been no significant changes in the external market environment or industry policies, no media reports or market rumors that could significantly impact the company’s stock trading prices, and no involvement of market hot concepts.

Additionally, the company expects its net profit attributable to shareholders of the listed company for 2025 to be between -470 million and -570 million yuan, and net profit excluding non-recurring gains and losses to be between -460 million and -560 million yuan. The company plans to reduce its holdings by no more than 176,630,744 shares from March 2, 2026, to September 1, 2026.

According to Tianyancha, Hebang Biotech was established on August 1, 2002, with a registered capital of 8,831,250,228 yuan. The legal representative is Zeng Xiaoping, and the registered address is Niuhua Town, Wutongqiao District, Leshan City. Its main businesses include chemical industry, pesticides, feed additives, glass and products, photovoltaic materials and products manufacturing, as well as salt and phosphate mining.

Currently, the company’s chairman is Zeng Xiaoping, the secretary of the board is Jiang Siying, with 5,386 employees, and the actual controller is He Zhengang.

The company holds stakes in 15 subsidiaries, including Sichuan Hebang Liujiashan Phosphate Mine Co., Ltd., PAN PACIFIC RESOURCES PTY LTD, Leshan Yongjiang Industrial Co., Ltd., Qianwei Hebang Shuncheng Salt Industry Co., Ltd., PAN PACIFIC INDUSTRIES PTY LTD, and others.

In terms of performance, the company’s operating revenue for 2022, 2023, and 2024 was 13.039 billion yuan, 8.824 billion yuan, and 8.547 billion yuan, respectively, with year-over-year growth of 30.55%, -32.33%, and -3.13%. Net profit attributable to shareholders was 3.807 billion yuan, 1.283 billion yuan, and 31.46 million yuan, with year-over-year growth of 26.12%, -66.29%, and -97.55%. During the same period, the company’s asset-liability ratio was 18.00%, 17.62%, and 35.90%.

Regarding risks, Tianyancha data shows the company has 145 internal Tianyan risks, 258 surrounding risks, 262 historical risks, and 326 warning risks.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.